

**BRISTOL-MYERS SQUIBB COMPANY**  
**WORLDWIDE NET SALES FROM CONTINUING OPERATIONS BY PRODUCT**  
**QUARTERLY SALES TREND ANALYSIS**  
(\$ in millions)

	2009							2010							% Change		FX Impact	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
<b>TOTAL</b>	4,322	4,665	8,987	4,788	13,775	5,033	18,808	4,807	4,768	9,575	4,798	14,373	5,111	19,484	2%	4%	-	1%
<b>Key Products</b>																		
Plavix	1,435	1,539	2,974	1,554	4,528	1,618	6,146	1,666	1,627	3,293	1,658	4,951	1,715	6,666	6%	8%	-	-
Avapro/Avalide	302	313	615	329	944	339	1,283	314	307	621	303	924	252	1,176	(26)%	(8)%	-	2%
Abilify <sup>(b)</sup>	589	643	1,232	653	1,885	707	2,592	617	633	1,250	608	1,858	707	2,565	-	(1)%	(1)%	-
Reyataz	322	331	653	360	1,013	388	1,401	373	357	730	375	1,105	374	1,479	(4)%	6%	(2)%	-
Sustiva Franchise <sup>(a)</sup>	292	312	604	315	919	358	1,277	335	331	666	342	1,008	360	1,368	1%	7%	(2)%	(1)%
Baraclude	152	179	331	191	522	212	734	216	223	439	228	667	264	931	25%	27%	4%	3%
Erbitux	164	173	337	179	516	167	683	166	172	338	159	497	165	662	(1)%	(3)%	1%	-
Sprycel	88	107	195	107	302	119	421	131	132	263	144	407	169	576	42%	37%	(3)%	1%
Ixempra	24	29	53	28	81	28	109	29	29	58	29	87	30	117	7%	7%	(3)%	-
Orencia	124	148	272	162	434	168	602	169	178	347	184	531	202	733	20%	22%	(1)%	-
Onglyza/Kombiglyze	-	-	-	20	20	4	24	10	28	38	47	85	73	158	*	*	-	-
<b>Mature Products and All Other<sup>(c)</sup></b>	830	891	1,721	890	2,611	925	3,536	781	751	1,532	721	2,253	800	3,053	(14)%	(14)%	(2)%	-

	2009							2010							% Change		FX Impact	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
<b>Net Sales by Therapeutic Area:</b>																		
Cardiovascular	1,892	2,050	3,942	2,055	5,997	2,118	8,115	2,129	2,069	4,198	2,086	6,284	2,111	8,395	-	3%	1%	-
Virology	794	848	1,642	890	2,532	981	3,513	945	929	1,874	963	2,837	1,017	3,854	4%	10%	(1)%	-
Oncology	407	450	857	447	1,304	437	1,741	435	444	879	443	1,322	478	1,800	9%	3%	-	1%
Neuroscience	621	660	1,281	668	1,949	727	2,676	635	650	1,285	618	1,903	715	2,618	(2)%	(2)%	(2)%	-
Immunoscience	124	148	272	162	434	168	602	169	178	347	184	531	202	733	20%	22%	(1)%	-
Metabolics	25	36	61	52	113	30	143	37	55	92	75	167	97	264	*	85%	(2)%	-
Other Therapeutic Areas	459	473	932	514	1,446	572	2,018	457	443	900	429	1,329	491	1,820	(14)%	(10)%	(6)%	(1)%

\* In excess of +/- 200%

(a) The Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla.

(b) Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

(c) Includes products which have lost their exclusivity in major markets, over the counter brands and \$15M of Recothrom sales in 2010.